Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Biovail Corp. International

(BIOVF)

Hemant Shah of HKS & Co. initiated coverage with a "buy" recommendation. Shah said

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE